EUVIMEDEUVIMED entdecken
Crossref

Expression-Guided Immunoinformatics Design of a Recombinant Multi-Epitope Vaccine Candidate for Triple-Negative Breast Cancer Incorporating a MyD88-Derived Immunomodulatory Domain

Moh Royhan Afnani, Volta Kellik Setiawan, Anwar Rovik

Natural and Life Sciences Communications · 24.08.2026 · 25 (4)

DOI: 10.12982/nlsc.2026.091 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Natural and Life Sciences Communications, online erschienen am 24.08.2026. Verfasst von Moh Royhan Afnani und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) remains a major therapeutic challenge because of its aggressive behavior, molecular heterogeneity, and limited subtype-specific targets. This study used an integrated immunoinformatics workflow to design a recombinant tumor-associated antigen-derived multi-epitope vaccine based on MMP1, CXorf61/CT83, and COL11A1, prioritized according to their tumor-to-normal transcript-expression ratios. Candidate cytotoxic T-lymphocyte, helper T-lymphocyte, and linear B-cell epitopes were screened for predicted HLA binding, antigenicity, allergenicity, toxicity, and IFN-γ-induction potential. The selected epitopes were assembled with PADRE, a MyD88-derived exploratory immunomodulatory domain, class-specific linkers, and a C-terminal histidine tag to generate a 621-amino-acid construct. Combined HLA class I and II analysis predicted 99.36% worldwide population coverage, with 3.14 epitope–HLA hits per individual. The construct was predicted to be antigenic, non-allergenic, soluble, and physicochemically compatible with recombinant production. Structural modeling yielded a ProSA Z-score of −7.43 and 97.45% of residues in favored Ramachandran regions, while disulfide engineering identified ten candidate intramolecular bridges. Docking produced an HDOCK score of −298.65 for the modeled vaccine–TLR4 complex, and flexibility analysis showed an average RMSF of 1.93 Å. Immune simulation predicted Th1-associated cytokine production, T-cell expansion, antibody responses, and memory-cell formation. Codon optimization generated a CAI of 0.95 and a GC content of 53.2%, followed by virtual cloning into pET-28a(+). These findings support the computational feasibility of the proposed vaccine candidate, which requires experimental validation of expression, antigen processing, HLA presentation, immunogenicity, safety, and antitumor activity.

Zitieren

APA

Afnani, M. R., Setiawan, V. K., & Rovik, A. (2026). Expression-Guided Immunoinformatics Design of a Recombinant Multi-Epitope Vaccine Candidate for Triple-Negative Breast Cancer Incorporating a MyD88-Derived Immunomodulatory Domain. Natural and Life Sciences Communications, 25(4). https://doi.org/10.12982/nlsc.2026.091

Vancouver

Afnani MR, Setiawan VK, Rovik A. Expression-Guided Immunoinformatics Design of a Recombinant Multi-Epitope Vaccine Candidate for Triple-Negative Breast Cancer Incorporating a MyD88-Derived Immunomodulatory Domain. Natural and Life Sciences Communications. 2026;25(4). doi:10.12982/nlsc.2026.091

BibTeX
@article{Afnani2026,
  author = {Afnani, Moh Royhan and Setiawan, Volta Kellik and Rovik, Anwar},
  title = {Expression-Guided Immunoinformatics Design of a Recombinant Multi-Epitope Vaccine Candidate for Triple-Negative Breast Cancer Incorporating a MyD88-Derived Immunomodulatory Domain},
  journal = {Natural and Life Sciences Communications},
  year = {2026},
  volume = {25},
  number = {4},
  doi = {10.12982/nlsc.2026.091}
}
Kostenlos starten →